The Nitrogen Is Bonded Directly To A Carbocyclic Ring Of The Tricyclo Ring System Patents (Class 546/100)
  • Patent number: 9845390
    Abstract: Provided are processes for producing fluorescent naphthalimide diesters of Formula (I), useful as fluorescent tracer dyes for fluid system leak detection, wherein each of R1 and R2 is, independently of the other, a saturated, linear hydrocarbon chain having from 2 to 10 carbon atoms; and each of Z1 and Z2 is, independently of the other, a fatty acid moiety having a saturated or unsaturated, linear or branched, hydrocarbon chain having from 8 to 24 carbon atoms, and from 0 to 4 double bonds. Also provided are compositions of the aforesaid diesters of Formula (I).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 19, 2017
    Assignee: Spectronics Corporation
    Inventor: Daniel Scott Tyson
  • Patent number: 9018377
    Abstract: The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: April 28, 2015
    Assignee: OPTI Medical Systems
    Inventors: Huarui He, Chao Lin
  • Publication number: 20150079625
    Abstract: The present invention provides a novel category of naphthalene-based two-photon fluorescent probes having a general formula I, wherein: X is selected from the X1, X2, X3 and X4; The mentioned two-photon fluorescent probes have a low fluorescence background in the non-tumor cells and tissues, and have a strong and specific fluorescent signal in the tumor cells and tissues. These probes have a certain level of water-solubility, while having good membrane permeability. In addition, they have a bigger effective two-photon absorption cross section. The compounds of the present invention also have a lower biotoxicity, phototoxicity and photobleaching. There is sufficient difference between the spectral range thereof and that of a biological sample.
    Type: Application
    Filed: March 5, 2012
    Publication date: March 19, 2015
    Applicants: DALIAN CHROMAS BIOSCIENCE CO., LTD, DALIAN UNIVERSITY OF TECHNOLOGY
    Inventors: Xiaojun Peng, Hua Zhang, Jiangli Fan, Jingyun Wang
  • Publication number: 20140147876
    Abstract: The invention relates to devices comprising a sensor layer capable of binding magnesium ions and a scavenging layer that preferentially binds to calcium ions in the presence of both magnesium ions and calcium ions. The sensor layers can comprise known or novel luminionophores. The invention further relates to methods of selectively detecting magnesium ion concentration in the presence of calcium ions.
    Type: Application
    Filed: November 29, 2012
    Publication date: May 29, 2014
    Applicant: IDEXX Laboratories, Inc.
    Inventors: Peter Chaoquan ZHU, Yingzi Wu
  • Publication number: 20130131006
    Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Patent number: 8420665
    Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: April 16, 2013
    Assignee: Northwestern University
    Inventors: Sui Huang, John Norton, Daniel Appella, Mark Witschl
  • Publication number: 20130074927
    Abstract: The invention provides highly fluorescent materials comprising a single (n=0) or a series (n=1, 2, etc.) of benzo heterocyclic systems. The photo-stable highly luminescent chromophores are useful in various applications, including in wavelength conversion films. Wavelength conversion films have the potential to significantly enhance the solar harvesting efficiency of photovoltaic or solar cell devices.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventor: NITTO DENKO CORPORATION
  • Publication number: 20130005759
    Abstract: MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.
    Type: Application
    Filed: January 21, 2011
    Publication date: January 3, 2013
    Inventors: Alexander Deiters, Douglas D. Young
  • Publication number: 20120329085
    Abstract: The invention provides reaction-based fluorescent probes for selective imaging of hydrogen sulfide in living cells.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 27, 2012
    Applicant: The Regents of The University of California
    Inventors: Christopher J. CHANG, Alexander R. Lippert, Vivian S. Lin
  • Patent number: 8338603
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4, R5, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: December 25, 2012
    Assignee: AbbVie Inc.
    Inventors: Arthur R. Gomtsyan, Robert G. Schmidt, Erol K. Bayburt, Jerome F. Daanen, Michael E. Kort
  • Publication number: 20120294808
    Abstract: A method of imaging using selective fluorescent emitters and compositions for imaging are described. The method can include contacting a specimen with a composition comprising at least one selective fluorescent emitter of Formulas I through IX and irradiating the specimen with an excitation wavelength. The fluorescence emitted by the selective fluorescent emitter can be detected to generate an image. Formulas I through IX are: wherein: R1=OR4 or NR3R4; R2=OR4, NR3R4, Cl, F or H; R3=H, CH3, C2H5, C3H7 or C4H9; R4=H, CH3, C2H5, C3H7 or C4H9; R5=H or CH2(CH2)nNR3R4; R6=H or CH2(CH2)nNR3R4; R7=OR4, NR3R4, Cl, F or H; R8=N-methylpyridinium or N-methyl-1,2,3,6-tetrahydropyridine; and n=1, 2 or 3.
    Type: Application
    Filed: November 9, 2010
    Publication date: November 22, 2012
    Applicant: UNIVERSITY OF MIAMI
    Inventor: James N. Wilson
  • Publication number: 20120183984
    Abstract: The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q+ is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q+.
    Type: Application
    Filed: July 22, 2010
    Publication date: July 19, 2012
    Applicant: OPTI MEDICAL SYSTEMS
    Inventors: Huarui He, Chao Lin
  • Publication number: 20120009683
    Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.
    Type: Application
    Filed: July 29, 2011
    Publication date: January 12, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kyle Richard GEE, Vladimir MARTIN
  • Publication number: 20110263457
    Abstract: We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.
    Type: Application
    Filed: July 1, 2011
    Publication date: October 27, 2011
    Inventors: Peter O. Krutzik, Garry Nolan
  • Publication number: 20110189096
    Abstract: To provide a central nervous system tissue-labeling composition labeling the central nervous tissue system. Also, another object of the present invention is to provide a method for non-invasively labeling the central nervous tissue system. Further, another object of the present invention is to provide a screening method using the above central nervous system tissue-labeling composition. A central nervous system tissue-labeling composition containing, as an active ingredient, at least one of compounds represented by the general formula (1) or (7).
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Kohei Watanabe, Taichi Shintou, Tsuyoshi Nomoto, Takeshi Miyazaki, Mie Okano, Toshio Tanaka, Yuhei Nishimura, Yasuhito Shimada
  • Publication number: 20110113572
    Abstract: The present application relates to a novel family of cationic naphthalimide compounds that can be used as a direct dye, and to a dye composition for the dyeing of keratin fibres, in particular human keratin fibres such as the hair, comprising, in a suitable dyeing medium, at least one such compound. The present application also relates to the dyeing process using this composition and its uses.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 19, 2011
    Applicant: L' OREAL S.A.
    Inventors: Tiina Luukas, Andrew Greaves, Hervé David
  • Publication number: 20100303719
    Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.
    Type: Application
    Filed: January 12, 2009
    Publication date: December 2, 2010
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Sui Huang, John Norton, Daniel Appella, Mark Witschi
  • Patent number: 7803197
    Abstract: Disclosed are thiol dyes of formula (1) wherein L1 is hydrogen; C1-C12alkyl; or phenyl-C1-C4alkyl; X is C1-C12alkylene, C2-C12alkenylene, C5-C10cycloalkylene, C5-C10arylene, or C5-C10arylene-C1-C10alkylene, which may by interrupted by —O—, —NH—, —S—, —CO—, o-SO2—; Y is the residue of an organic dye Z is a group of formula (1b) or —C?N; wherein A is O; S; or N-L2; B is L3; —OL3; —NL3L4; or —SL3; and L2, L3 and L4, independently from other are hydrogen; C1-C12alkyl; C5-C12aryl-C1-C12alkyl. The compounds are useful for the dyeing of organic materials, such as keratin fibers, preferably human hair.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: September 28, 2010
    Assignee: Ciba Corporation
    Inventors: Victor Paul Eliu, Beate Fröhling, Dominique Kauffmann
  • Publication number: 20100168428
    Abstract: The present invention generally relates to environment-sensitive fluorophores, including environment-sensitive fluorophores for reporting protein/protein and peptide/protein interactions. In one aspect, the present invention is directed to compounds and salts thereof, compositions and methods useful in determining biological interactions. In some cases, the compounds of the present invention are environment-sensitive fluorophores that have spectroscopic behavior that may depend on factors such as the physicochemical properties of the surrounding environment. The compounds of the present invention can be used, in certain embodiments, to monitor ions, small molecules, and biological processes such as protein folding, protein-protein interactions and phosphorylation events.
    Type: Application
    Filed: February 26, 2008
    Publication date: July 1, 2010
    Applicant: Massachusetts Institute of Technology
    Inventors: Barbara Imperiali, Galen S. Loving
  • Publication number: 20090312363
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone deacetylase activity (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, hair loss, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.
    Type: Application
    Filed: February 14, 2007
    Publication date: December 17, 2009
    Inventors: James Elliot Bradner, Ralph Mazitschek, Tang Weiping, Stuart S. Schreiber
  • Publication number: 20090215815
    Abstract: A pharmaceutical composition comprising a compound of Formula I wherein R1 is selected from, inter alia, alkyl, aryl-loweralkyl, heterocycle-loweralkyl, loweralkyl-carbonate; optionally substituted amino; benimidaz-2-yl; optionally substituted phenyl; loweralkyl-(R5)(R6) wherein one of R5 and R6 is selected from H and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxycarbonyl; NHCH2CH2OX wherein X represents an in vivo hydrolyzable ester; and R2 and R3 are independently selected from H, NO2, halo, di(loweralkyl)amino, cyano, C(O)OH, phenyl-S—, loweralkyl, and Z(O)OR7 wherein Z is selected from C and S and R7 is selected from H, loweralkylamino and arylamino; or pharmaceutically acceptable salts or certain in vivo hydrolyzable esters or amides thereof, in an amount effective to inhibit neurotrophin-mediated activity, and a suitable carrier, is described.
    Type: Application
    Filed: April 28, 2009
    Publication date: August 27, 2009
    Inventors: Ashok Tehim, Xiannong Chen
  • Publication number: 20090118321
    Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods for making such derivatives through hydrolysis of known compounds.
    Type: Application
    Filed: May 7, 2007
    Publication date: May 7, 2009
    Applicant: Unibioscreen S.A.
    Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van den Hove, Francis Darro, Robert Kiss
  • Publication number: 20090029389
    Abstract: The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.
    Type: Application
    Filed: July 25, 2008
    Publication date: January 29, 2009
    Applicant: INVITROGEN CORPORATION
    Inventors: Kyle Richard Gee, Vladimir Martin
  • Patent number: 6989390
    Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X? or R1 is —(CH2)nN+HR3R4 X? or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X?? sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X? is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: January 24, 2006
    Assignee: Xanthus Life Sciences, Inc.
    Inventors: Alfred M. Ajami, David O. Barlow
  • Patent number: 6890377
    Abstract: Rylene dyes of the general formula I where R is hydrogen; unsubstituted or substituted C1-C30-alkyl, aryl or hetaryl; R? is unsubstituted or substituted C2-C30-alkyl or C5-C8-cycloalkyl, or substituted methyl; n is 0 or 1, their preparation and use for coloring high-molecular-weight organic and inorganic materials, and aminorylene-3,4-dicarboximide of the formula IV as their intermediates.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: May 10, 2005
    Assignees: BASF Aktiengesellschaft, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Arno Böhm, Matthias Krieger, Stefan Becker, Klaus Müllen
  • Patent number: 6768010
    Abstract: Organophotoreceptors comprise an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: a) a charge transport compound having the formula where R1 and R2 are, independently, hydrogen, an alkyl group, a heterocyclic group, an alkaryl group or an aryl group; X is an aromatic group; Y is an (N,N-disubstituted) arylamine group, such as a (N,N-disubstituted) arylamine group, a carbazole group or a julolidine group; Z is (CH2)m group where m is an integer between 1 and 30 where one or more of the methylene groups is optionally replaced by O, S, C═O, O═C—O, O═C—NR3, sulfoxide, sulfate, phosphate, an aryl group, urethane, urea, a NR4 group, a CHR5 group, or a CR6R7 group where R3, R4, R5, R6, and R7 are, independently, H, hydroxyl, thiol, an amine group, an alkyl group, a heterocyclic group, an alkaryl group, or an aryl group; and E is an epoxy group; and (b) a charge generating co
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: July 27, 2004
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Zbigniew Tokarski, Nusrallah Jubran, Vytautas Getautis, Maryte Daskeviciene, Edmundas Montrimas, Valentas Gaidelis
  • Patent number: 6693198
    Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X− or R1 is —(CH2)nN+HR3R4 X− or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X− sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X− is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: February 17, 2004
    Assignee: Xanthus Life Sciences, Inc.
    Inventors: Alfred M. Ajami, David O. Barlow
  • Patent number: 6559306
    Abstract: This invention relates to new fluorescent or non-fluorescent dye compounds having a terminal hydroxy, carboxylic acid/ester or amino group and a process for their preparation. The new fluorescent or non-fluorescent dye compounds are useful as colorants for preparing colored synthetic polymer resins with pigmentary properties, for dyeing or printing homo- or mixed synthetic, semi-synthetic or natural polymers or substrates or for preparing inks. The dye compounds provide excellent properties, especially high temperature stability and easy applicability.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: May 6, 2003
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Bansi Lal Kaul, Jean-Christophe Graciet
  • Patent number: 6486319
    Abstract: The invention relates to rylene dyes of the general formula (I), wherein the variables have the following meanings: R represents hydrogen; optionally substituted C1-C30 alkyl-C5-C8-cycloalkyl, aryl or hetaryl; R′ represents optionally substituted C2-C30 alkyl or C5-C8 cycloalkyl, substituted methyl; and n is 0 or 1. The invention also relates to the preparation and use of said dyes for coloring highly molecular organic and inorganic materials and to 9-amino-perylene-3,4-dicarboxylic acid imides (Va) as their intermediate products.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: November 26, 2002
    Assignees: BASF Aktiengesellschaft, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Arno Böhm, Heinrich Schmeisser, Stefan Becker, Klaus Müllen
  • Patent number: 6410505
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: June 25, 2002
    Assignee: Microbiomed Corp.
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 6358746
    Abstract: Fluorescent compounds of the formula: wherein R1 and R2 are either both SO3M, or one of R1 and R2 is SO3M and the other is COOM, where M is selected from the group consisting of H, Na, K, Rb, Cs, Li or ammonium, are described and claimed. These inert flurorescent compounds have been found to be resistant to oxidizing biocides. One process for making these compounds is described and claimed as the condensation between a 1,8-naphthalic anhydride possessing the desired functionalities and the appropriately substituted o-phenylene diamine. Alternatively, o-amino-nitro-aromatics may be condensed with the various 1,8-naphthalic anhydrides when the in situ reduction of the nitro group is accomplished with a suitable reducing agent such as iron powder. The resulting fluorescent compounds can be used as inert fluorescent tracers in industrial water systems.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: March 19, 2002
    Assignee: Nalco Chemical Company
    Inventors: Barbara E. Moriarty, Jerry L. Reddinger
  • Patent number: 6248890
    Abstract: A fluorescent naphthalimide diester dye that is miscible or soluble in a variety of organic compounds such as, for example, mineral oil, polyalkylene glycols, polyolesters, motor oil, gear oil, synthetic oils, and polyalphaolefins, is provided. The fluorescent naphthalimide diester is useful as a tracer to detect leaks within a fluid systems such as, for example, refrigerant systems, transmission systems, and hydraulic systems. The fluorescent naphthalimide diester dye is comprised of a chromophore having the following structure: wherein: Z and Z′ are the same or different, and are esters attached to saturated or unsaturated linear or branched hydrocarbon chains attached thereto, having from 8 to 24 carbon atoms in length, preferably from 12 to 22 carbon atoms in length, most preferably from 16 to 20 carbon atoms in length, and from 1 to 4 double bonds, most preferably 2 to 3 double bonds.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: June 19, 2001
    Assignee: Day-Glo Color Corp.
    Inventors: Wayne R. Likavec, Thomas C. DiPietro
  • Patent number: 6177570
    Abstract: Bisimides of the formula I where R1, R2, R3 and R4 have the meanings stated in the description, are prepared in a process in which the corresponding dicarboxylic anhydrides of the formulae II and III R1—CO—O—CO—R2  (II) R3—CO—O—CO—R4  (III), are reacted with an amine of the formula H2N—R—NH2 in the presence of a tertiary amine.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: January 23, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Wolfgang Viergutz, Stefan Koser
  • Patent number: 6150306
    Abstract: A dye composition has the formula: ##STR1## where R.sup.1 and R.sup.2 are the same or different and are selected from (A) C.sub.2 -C.sub.12 alkyloxyalkyl, and (B) C.sub.9-12 alkyl, (A) comprising from about 30 to 80 mole % of the R groups, (B) comprising 20 to about 70 mole % of the R groups. The dye composition is useful as a fluorescent tracer in refrigerant lubricants of the polyol ester types used in non-Freon refrigerants.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: November 21, 2000
    Assignee: Morton Internatioanl Inc.
    Inventor: Michael R. Friswell
  • Patent number: 6133259
    Abstract: Amyloid binding compounds which are non-azo derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing non-azo derivatives of Chrysamine G and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using non-azo Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using non-azo Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.
    Type: Grant
    Filed: November 9, 1998
    Date of Patent: October 17, 2000
    Assignee: University of Pittsburgh
    Inventors: William E. Klunk, Jay W. Pettegrew, Chester A. Mathis, Jr.
  • Patent number: 5998621
    Abstract: This invention relates to colorants comprising naphthalimide base groups with specific water-solubilizing pendant moieties attached. These pendant moieties are based upon aryloxypolyoxyalkylene groups which provide the desired solubility to the naphthalimide colorant compound. Furthermore, the aryloxypolyoxyalkylene groups facilitate the further addition of other pendant groups to the base compound which increase or decrease the solubility of the resultant naphthalimide derivative colorant as well. Such modified naphthalimides are useful as fluorescent colorants, particularly within other liquid media (both aqueous and non-aqueous) without the necessary inclusion of surfactants, solvents, diluents, and the like. Methods of making such colorants, as well as the aryloxypolyoxyallylene intermediates, are also contemplated within this invention.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: December 7, 1999
    Assignee: Milliken & Company
    Inventor: Robert L. Mahaffey, Jr.
  • Patent number: 5981753
    Abstract: Disclosed herein are compounds pharmaceutical compositions containing same of the formula1. A compound of the Formula ##STR1## wherein X, X', X" and X'", A, B, D, R, and R' are as identified in the specification and their preparation. Pharmaceutical compositions containing same can be used in the treatment of cancer.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: November 9, 1999
    Assignee: BASF Aktiengesellschaft
    Inventors: Gerhard Keilhauer, Cynthia Romerdahl, Miguel Fernandez Brana, Xiao-Dong Qian, Peter Bousquet, Jose Maria Castellano Berlanga, Marina Moran Moset, Maria Jesus Perez De Vega
  • Patent number: 5918269
    Abstract: Novel naphthalimide-derivative colorants are provided which are present in a neat liquid state at ambient temperature and pressure. Such colorants are produced through the reaction between 4-chloro (or bromo)-1,8 naphthalic anhydride and at least one etheramine, at least one branched alkylamine, or mixtures thereof. The inventive colorants are excellent leak detection agents for refrigeration and air conditioning systems. These naphthalimide derivatives are completely miscible in all different types of standard refrigeration and air conditioning lubricants. Furthermore, since these colorants are liquid, they are not susceptible to crystallizing within such systems. Thus, the inventive naphthalimide leak detecting agents cannot cause the failure of such machinery due to the crystallization of colorant and subsequent clogging of system compressors. Methods of making and using such inventive naphthalimide-derivative colorants are also disclosed.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: June 29, 1999
    Assignee: Milliken & Company
    Inventor: Robert L. Mahaffey, Jr.
  • Patent number: 5917045
    Abstract: A class of predominantly hydrophilic 1,8-naphthalimide dyes. The dye contains at least two 1,8-naphthalimide ring systems, joined by a spacer moiety. Each of the 1,8-naphthalimide ring system has a ring nitrogen atom and bears, at the 4 position, an amino nitrogen atom, carrying a hydrogen. The remaining unsatisfied valences, if present, of the ring nitrogen atoms or the amino nitrogen atoms, or all, are occupied by one or more alkyl substituents. Each of the 1,8-naphthalimide ring system is free of an azo substituent and is also free of a nucleofuge. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species can cause structural changes in lipid and any associated proteins and polypeptides, extra- or intra-cellular or transmembrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 29, 1999
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5858930
    Abstract: 1,8-Naphthalimide derivatives of Formula (I) are useful as fluorescent dyes: ##STR1## wherein R.sup.1 and R.sup.2 are each independently selected from the group consisting of branched alkyl groups containing 7-8 carbon atoms and alkyloxyalkyl groups containing 4 to 24 carbon atoms.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: January 12, 1999
    Assignee: United Color Manufacturing, Inc.
    Inventors: Bharat Desai, Michael J. Smith
  • Patent number: 5840903
    Abstract: This invention relates to compounds of the formula: ##STR1## or a pharmaceutically acceptable salt thereof wherein Z is selected from the group consisting of ##STR2## R.sub.1 is alkoxy of one to six carbon atoms; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and are selected from the group consisting of hydrogen, halogen, CF.sub.3, hydroxy, alkoxy of one to six carbon atoms, acyl of two to seven carbon atoms, amino, amino substituted by one or two alkyl groups of one to six carbon atoms, C.sub.2 -C.sub.7 acylamino, aminocarbonyl, aminosulfone optionally substituted by one or two alkyl groups of one to six carbon atoms, C.sub.1 -C.sub.6 alkylsulfone and nitro;m is 1 or 2;X is O or NR.sub.7 ; andR.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: November 24, 1998
    Assignee: G. D. Searle & Co.
    Inventors: Daniel Lee Flynn, Robert L. Shone
  • Patent number: 5817820
    Abstract: The present invention relates to optical isomers of quinoline compounds of Formula (IA) or Formula (IA'), their pharmaceutically acceptable salts and their intermediates: ##STR1## In the above formulae, A represent nitrogen or ##STR2## in which Y represents hydrogen, halogen such as fluorine or chlorine, lower alkyl or lower alkoxy such as methoxy, or together with R.sub.1 forms --CH.sub.2 CH.sub.2 CH.sub.2 --, CH.sub.2 CH.sub.2 CH(CH.sub.3)--, --OCH.sub.2 CH.sub.2 --, --OCH.sub.2 CH(CH.sub.3)--, --SCH.sub.2 CH.sub.2 -- or --SCH.sub.2 CH(CH.sub.3)--; R.sub.1 is as defined above or represents straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms, a straight chain or cyclic lower alkyl group having 1 to 3 carbon atoms which is substituted with a halogen atom, a phenyl group or a phenyl group substituted with one or two halogen atoms, such as ethyl, cyclopropyl or 2,4-difluorophenyl; R.sub.
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: October 6, 1998
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Wan Joo Kim, Tae Ho Park, Moon Hwan Kim, Jewn Giew Park, Bong Jin Kim
  • Patent number: 5663449
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 2, 1997
    Assignee: Hoechst Marion Roussel, Inc.
    Inventor: Joseph T. Strupczewski
  • Patent number: 5658911
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: August 19, 1997
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau, Edward J. Glamkowski, Yulin Chiang, Grover C. Helsley
  • Patent number: 5654319
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 5, 1997
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Edward J. Glamkowski, Yulin Chiang
  • Patent number: 5641782
    Abstract: This invention relates to 3-Pyrimidinyl Bisnaphthalimides as Anticancer Agents and pharmaceutically acceptable salts thereof, of the formula: ##STR1## and processes for the preparation of such compounds, pharmaceutical composition containing such compounds, and methods of using such compounds to treat cancer, particularly solid tumor carcinomas, in mammals.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: June 24, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Jung-Hui Sun, Steven P. Seitz
  • Patent number: 5639764
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents, the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 17, 1997
    Assignee: Hoechst-Marion-Roussel, Inc.
    Inventors: Edward J. Glamkowski, Yulin Chiang
  • Patent number: 5637710
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: June 10, 1997
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau
  • Patent number: RE37729
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: June 4, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Edward J. Glamkowski, Yulin Chiang, Joseph T. Strupczewski, Kenneth J. Bordeau, Peter A. Nemoto, John J. Tegeler
  • Patent number: RE39265
    Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: September 5, 2006
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Joseph T. Strupczewski, Kenneth J. Bordeau, Edward J. Glamkowski, Yulin Chiang, Grover C. Helsley